Latest filings (excl ownership)
424B3
Prospectus supplement
21 Mar 24
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
21 Mar 24
424B3
Prospectus supplement
15 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Mar 24
424B3
Prospectus supplement
14 Mar 24
8-K
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
14 Mar 24
8-K
Regulation FD Disclosure
11 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
RW
Registration withdrawal request
1 Mar 24
S-1/A
IPO registration (amended)
6 Feb 24
D
$250.00 k in equity, sold $250.00 k, 1 investor
23 Jan 24
424B3
Prospectus supplement
10 Jan 24
8-K
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
8 Jan 24
424B3
Prospectus supplement
28 Dec 23
EFFECT
Notice of effectiveness
28 Dec 23
S-1/A
IPO registration (amended)
26 Dec 23
CORRESP
Correspondence with SEC
26 Dec 23
CORRESP
Correspondence with SEC
22 Dec 23
S-1/A
IPO registration (amended)
21 Dec 23
CORRESP
Correspondence with SEC
21 Dec 23
UPLOAD
Letter from SEC
21 Dec 23
S-1/A
IPO registration (amended)
15 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Dec 23
S-1
IPO registration
13 Dec 23
8-K
Entry into a Material Definitive Agreement
13 Dec 23
8-K
Entry into a Material Definitive Agreement
30 Nov 23
8-K
Departure of Directors or Certain Officers
20 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
9 Nov 23
8-K
Results of Operations and Financial Condition
30 Oct 23
S-1/A
IPO registration (amended)
27 Oct 23
EFFECT
Notice of effectiveness
17 Oct 23
DEF 14A
Definitive proxy
16 Oct 23
S-3/A
Shelf registration (amended)
12 Oct 23
CORRESP
Correspondence with SEC
12 Oct 23
PRE 14A
Preliminary proxy
6 Oct 23
S-3/A
Shelf registration (amended)
25 Aug 23
UPLOAD
Letter from SEC
22 Aug 23
D
$2.11 mm in equity, sold $2.11 mm, 10 investors
11 Aug 23
S-3
Shelf registration
9 Aug 23
Latest ownership filings
4
DAVID P PERRY
13 Feb 24
SC 13G/A
MMCAP International Inc. SPC
13 Feb 24
SC 13D/A
David P. Perry 2015 Trust
12 Feb 24
SC 13D/A
David P. Perry 2015 Trust
25 Jan 24
4
DAVID P PERRY
10 Jan 24
4
DAVID P PERRY
20 Dec 23
4
Richard H Carmona
20 Dec 23
4
RISA J LAVIZZO-MOUREY
20 Dec 23
4
Kristin Wynholds
20 Dec 23
4
Geoffrey M. Parker
20 Dec 23
4
Andrew J. Armanino
20 Dec 23
4
Leslie A. Miller
20 Dec 23
4
Elder Granger
20 Dec 23
4
FRANK KARBE
20 Dec 23
4
Mark A. Berman
20 Dec 23
3
Leslie A. Miller
7 Dec 23
SC 13D/A
David P. Perry 2015 Trust
14 Aug 23
SC 13G
MMCAP International Inc. SPC
31 Jul 23
4
DAVID P PERRY
31 Jul 23
4
Mark A. Berman
31 Jul 23
4
Andrew J. Armanino
31 Jul 23
4
Elder Granger
31 Jul 23
4
FRANK KARBE
31 Jul 23
4
Geoffrey M. Parker
31 Jul 23
4
Richard H Carmona
9 Jun 23
4
Elder Granger
9 Jun 23
4
Andrew J. Armanino
9 Jun 23
4
RISA J LAVIZZO-MOUREY
9 Jun 23
4
Geoffrey M. Parker
9 Jun 23
4
DAVID P PERRY
9 Jun 23
4
Elder Granger
18 May 23
4
Mark Heinen
21 Apr 23
4
Kristin Wynholds
21 Apr 23
4
Mark A. Berman
21 Apr 23
SC 13D/A
David P. Perry 2015 Trust
21 Apr 23
3
Initial statement of insider ownership
17 Apr 23
SC 13G/A
Mountain Crest Capital LLC
13 Apr 23
4
DAVID P PERRY
12 Apr 23
4
FRANK KARBE
12 Apr 23
4
Geoffrey M. Parker
12 Apr 23